EuroBiotech Report—Bayer, Merck, F-star, Philogen and roxa data by Nick Paul Taylor Thursday, May 16, 2019 In this week's EuroBiotech Report, Bayer pumps $150 million into cell therapies, Merck KGaA retools F-star pact and Philogen raises $70 million.
FibroGen sinks as roxadustat safety results confuse investors by Nick Paul Taylor Friday, May 10, 2019 Shares in FibroGen plummeted as the wording of its number-free statement raised concerns about the safety of the kidney disease drug.
FibroGen’s renal anemia drug closer to EU filing by Phil Taylor Thursday, September 20, 2018 FibroGen’s partner Astellas has reported phase 3 data that could support filings of their HIF inhibitor in Europe as an oral alternative to EPO.
Akebia, Keryx to merge, creating kidney disease specialist by Nick Paul Taylor Thursday, June 28, 2018 The combined company will own potentially complementary kidney disease drugs and a sales force to promote them.
Kadmon clinical POC data raise expectations for IPF drug by Nick Paul Taylor Tuesday, February 13, 2018 The ROCK2 inhibitor had a stronger effect on FVC than standard of care, but the lack of detail in the top-line data leave scope for doubts.
FibroGen soars as IPF data paint pamrevlumab as a blockbuster by Nick Paul Taylor Tuesday, August 8, 2017 Shares in the biotech shot up 60% after it posted phase 2 data that suggest it can muscle in on a market fought over by Boehringer and Roche.
Prolific dealmakers Akebia and Vifor pen anemia drug pact by Nick Paul Taylor Tuesday, May 16, 2017 Vifor Pharma has struck a deal to sell Akebia Therapeutics’ phase 3 oral anemia drug vadadustat through its network of U.S. dialysis centers.
Akebia, Otsuka pen $865M expansion to anemia pill pact by Nick Paul Taylor Wednesday, April 26, 2017 Otsuka Pharmaceutical has expanded its anemia pact with Akebia Therapeutics.
10. GlaxoSmithKline by Ben Adams GlaxoSmithKline has one of the lowest R&D budgets in percentage of revenue terms of its peers; although its research budget was slightly up on 2015, this is still markedly down from the around £4 billion it was spending in 2012-13.
Phase 3 hit tees FibroGen, AstraZeneca up for anemia filing by Nick Paul Taylor Monday, January 30, 2017 FibroGen has posted positive phase 3 data on its AstraZeneca-partnered anemia drug.
